Searched for: in-biosketch:true
person:zelefm01
Discordance of patient- and physician-reported toxicities in two prospective trials of stereotactic body radiotherapy (SBRT) for localized prostate cancer. [Meeting Abstract]
Patel, Akshat; Badia, Rohit R.; Amini, Armon; Kung, Christopher; Kusin, Samuel B.; Neufeld, Sarah; Mannala, Samantha; Garant, Aurelie; Hannan, Raquibul; Timmerman, Robert D.; Zelefsky, Michael J.; Folkert, Michael Ryan; Desai, Neil Bipinchandra
ISI:000771008900250
ISSN: 0732-183x
CID: 5531302
Determining interobserver variability in prostate bed CTV target delineation using MRI [Meeting Abstract]
Sritharan, K.; Akhiat, H.; Cahill, D.; Choi, S. L.; Choudhury, A.; Chung, P.; Diaz, J.; Dysager, L.; Hall, W.; Kerkmeijer, L.; Lawton, C. A.; Murray, J.; Nyborg, C. J.; Pos, F. J.; Rigo, M.; Schytte, T.; Sidhom, M.; Sohaib, A.; Tan, A.; van Zyp, J. van der Voort; Vesprini, D.; Zelefsky, M. J.; Tree, A.
ISI:000806764200144
ISSN: 0167-8140
CID: 5531322
A Novel Approach to Vessel-Sparing Prostate Radiotherapy Using MR-Only Simulation and Non-Contrast MR Angiography: Vessel Delineation Feasibility and SBRT Dosimetric Analysis [Meeting Abstract]
Haseltine, J.; Tyagi, N.; Burleson, S.; Akin, O.; Zelefsky, M. J.
ISI:000892639300480
ISSN: 0360-3016
CID: 5531352
Combined Brachytherapy and Ultra-Hypofractionated Radiotherapy for Intermediate-Risk Prostate Cancer: Comparison of Toxicity Outcomes Using a High-Dose Rate (HDR) vs. Low-Dose Rate (LDR) Brachytherapy Boost [Meeting Abstract]
Kollmeier, M. A.; Gorovets, D.; Flynn, J.; McBride, S.; Brennan, V. S.; Beaudry, J.; Cohen, G.; Damato, A. L.; Zhang, Z.; Zelefsky, M. J.
ISI:000892639300487
ISSN: 0360-3016
CID: 5531362
A Multicenter Prospective Trial of Electronic Skin Surface Brachytherapy (ESSB) for Cutaneous Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC): Cosmesis, Quality of Life (QoL) and Adverse Events (AEs) [Meeting Abstract]
Kuo, A. M. S.; Lee, E. H.; Rossi, A. M.; Nehal, K. S.; Cordova, M. A.; Steckler, A. M.; Lian, M.; Cohen, G.; Zhang, Z.; Zelefsky, M. J.; Kasper, M. E.; Barker, C. A.
ISI:000892639302032
ISSN: 0360-3016
CID: 5531372
Focal Dose Intensification to the Dominant Intraprostatic Lesion (DIL) Using an MR-Linac Adaptive-Planning Approach for Prostate Cancer: Dosimetric Outcomes and Early Toxicity [Meeting Abstract]
Brennan, V. S.; Burleson, S.; Kostrzewa, C.; Scripes, P. G.; Subashi, E.; Zhang, Z.; Tyagi, N.; Zelefsky, M. J.
ISI:000892639300461
ISSN: 0360-3016
CID: 5531332
Quantitative Relaxometry for Target Localization and Response Assessment in Ultra-Hypofractionated MR-Guided Radiotherapy to the Prostate and DIL [Meeting Abstract]
Subashi, E.; LoCastro, E.; Apte, A.; Zelefsky, M. J.; Tyagi, N.
ISI:000892639302093
ISSN: 0360-3016
CID: 5531382
Favorable toxicity of chemoradiation for muscle-invasive bladder cancer in elderly, frail patients. [Meeting Abstract]
Moore, Assaf; Zhang, Zhigang; Bochner, Bernard H.; Donahue, Timothy F.; Rosenberg, Jonathan E.; Iyer, Gopa; Funt, Samuel Aaron; Bajorin, Dean F.; Teo, Min Yuen; Aggen, David Henry; Gorovets, Daniel; Guttmann, David; Zelefsky, Michael J.; Kollmeier, Marisa
ISI:000771008900514
ISSN: 0732-183x
CID: 5531312
An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiation
Slevin, Finbar; Aitken, Katharine; Alongi, Filippo; Arcangeli, Stefano; Chadwick, Eliot; Chang, Ah Ram; Cheung, Patrick; Crane, Christopher; Guckenberger, Matthias; Jereczek-Fossa, Barbara Alicja; Kamran, Sophia C; Kinj, Rémy; Loi, Mauro; Mahadevan, Anand; Massaccesi, Mariangela; Mendez, Lucas C; Muirhead, Rebecca; Pasquier, David; Pontoriero, Antonio; Spratt, Daniel E; Tsang, Yat Man; Zelefsky, Michael J; Lilley, John; Dickinson, Peter; Hawkins, Maria A; Henry, Ann M; Murray, Louise J
INTRODUCTION:Stereotactic Ablative Radiotherapy (SABR) is increasingly used to treat metastatic oligorecurrence and locoregional recurrences but limited evidence/guidance exists in the setting of pelvic re-irradiation. An international Delphi study was performed to develop statements to guide practice regarding patient selection, pre-treatment investigations, treatment planning, delivery and cumulative organs at risk (OARs) constraints. MATERIALS AND METHODS:Forty-one radiation oncologists were invited to participate in three online surveys. In Round 1, information and opinion was sought regarding participants' practice. Guidance statements were developed using this information and in Round 2 participants were asked to indicate their level of agreement with each statement. Consensus was defined as ≥75% agreement. In Round 3, any statements without consensus were re-presented unmodified, alongside a summary of comments from Round 2. RESULTS:Twenty-three radiation oncologists participated in Round 1 and, of these, 21 (91%) and 22 (96%) completed Rounds 2 and 3 respectively. Twenty-nine of 44 statements (66%) achieved consensus in Round 2. The remaining 15 statements (34%) did not achieve further consensus in Round 3. Consensus was achieved for 10 of 17 statements (59%) regarding patient selection/pre-treatment investigations; 12 of 13 statements (92%) concerning treatment planning and delivery; and 7 of 14 statements (50%) relating to OARs. Lack of agreement remained regarding the minimum time interval between irradiation courses, the number/size of pelvic lesions that can be treated and the most appropriate cumulative OAR constraints. CONCLUSIONS:This study has established consensus, where possible, in areas of patient selection, pre-treatment investigations, treatment planning and delivery for pelvic SABR re-irradiation for metastatic oligorecurrence and locoregional recurrences. Further research into this technique is required, especially regarding aspects of practice where consensus was not achieved.
PMID: 34560186
ISSN: 1879-0887
CID: 5194892
Second malignancy (SM) in prostate cancer patients treated with SBRT and other contemporary radiation techniques [Comment]
Blanchard, Pierre; Zelefsky, Michael J; Bossi, Alberto; Chargari, Cyrus; Cosset, Jean-Marc
PMID: 34627937
ISSN: 1879-0887
CID: 5529612